$NTLA SEC Filings

Filed On	Filing
06 Oct 2026	Form 4: Dube Michael P, VP, Chief Accounting Officer Sold 1,864 shares ($23.2K)
05 Oct 2026	144
08 Sep 2026	8-K: Regulation FD Disclosure; Other Events Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)
04 Sep 2026	8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
24 Aug 2026	Form 4: Leonard John M, Director Sold 19,890 shares ($251K) · Sold 2,785 shares ($36.2K)
20 Aug 2026	144
07 Aug 2026	SCHEDULE 13G
06 Aug 2026	10-Q
06 Aug 2026	8-K: Results of Operations and Financial Condition
24 Jul 2026	Form 4: Dulac Edward J Iii, EVP, Chief Financial Officer Sold 8,111 shares ($91.2K)
06 Jul 2026	Form 4: Dube Michael P, VP, Chief Accounting Officer Sold 2,641 shares ($44.3K)
06 Jul 2026	Form 4: Dulac Edward J Iii, EVP, Chief Financial Officer Sold 4,677 shares ($84.2K)
02 Jul 2026	144
15 Jun 2026	8-K: Regulation FD Disclosure; Other Events
10 Jun 2026	Form 4: Verwiel Frank, Director Received 9,200 shares as a grant or award · Granted 13,300 Stock Option (right to buy)
10 Jun 2026	Form 4: Keresty Georgia, Director Received 9,200 shares as a grant or award · Granted 13,300 Stock Option (right to buy)
10 Jun 2026	Form 4: Goodman Jesse, Director Received 9,200 shares as a grant or award · Granted 13,300 Stock Option (right to buy)
10 Jun 2026	Form 4: Goff Brian, Director Received 9,200 shares as a grant or award · Granted 13,300 Stock Option (right to buy)
10 Jun 2026	Form 4: Cohen Fred E, Director Received 9,200 shares as a grant or award · Granted 13,300 Stock Option (right to buy)
10 Jun 2026	Form 4: Chase William J, Director Received 9,200 shares as a grant or award · Granted 13,300 Stock Option (right to buy)

Comments